Protalix BioTherapeutics, Inc. (PLX) Ownership

NYSE American: PLXTop holders, insider trades and short interest.

PLX ownership summary

as of October 18, 2026
Institutions
23.7%
of shares outstanding
Insiders
3.88%
of shares outstanding
Shares outstanding
80.6M
Float
77.4M
shares available to trade
Short interest
3.93%
3.0M shares short
Days to cover
4.16
short interest down 4.0% vs prior month
  • Institutions 23.73%
  • Insiders 3.88%
  • Other investors 72.39%

PLX insider transactions

latest 4
Protalix BioTherapeutics, Inc. insider transactions
DateNameTransactionPriceSharesValue
2025-12-19Dror BashanBuy$1.8156,000$101,360
2025-11-18Amos Bar-ShalevSell$1.87168$314
2025-11-18Amos Bar-ShalevSell$1.87168$314
2025-06-10Aharon SchwartzBuy$1.60129,000$206,400

Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.

PLX shares outstanding

Shares outstanding

Year-end shares outstanding, adjusted for splits.

Who owns PLX

Institutional investors own 23.7% of Protalix BioTherapeutics's shares and insiders 3.88%. Short interest is 3.93% of the float, or 4.16 days of average trading volume. The share count rose 742.8% since 2014.

Related: PLX analyst forecast, PLX key metrics. See the PLX stock overview for the latest quote and news.

PLX ownership FAQ

What percentage of Protalix BioTherapeutics is owned by institutions?

Institutions hold 23.7% of Protalix BioTherapeutics's shares outstanding; insiders hold 3.88%.

What is Protalix BioTherapeutics's short interest?

3.0M shares of Protalix BioTherapeutics were sold short, 3.93% of the float; at the average daily volume it would take 4.16 days to cover.

Are insiders buying or selling Protalix BioTherapeutics?

Of the latest 4 reported insider transactions in Protalix BioTherapeutics (since June 10, 2025), 2 were purchases and 2 were sales.

How many shares of Protalix BioTherapeutics are outstanding?

Protalix BioTherapeutics has 80.6M shares outstanding, of which 77.4M are in the public float.

Biotechnology: ownership